Skip to main content
Premium Trial:

Request an Annual Quote

Claritas Genomics Receives NY State Approval for Dx Tests

NEW YORK (GenomeWeb) – Claritas Genomics announced today that it has received New York State Department of Health approval to start offering its Clinical Exome and Pediatric Neurology Region of Interest diagnostic tests in New York.

The company — which was created by Boston Children's Hospital and Cincinnati Children's Hospital in partnership with Cerner, Wuxi NextCode Genomics, and Thermo Fisher Scientific — offers the Clinical Exome test for people with complex, multi-systemic symptoms, or conditions with genetic and phenotypic heterogeneity.

The Pediatric Neurology Region of Interest focuses on eight neurological regions, including neuromuscular disorders, movement disorders, epilepsy and seizures, brain malformations, developmental delay and intellectual disability, hereditary peripheral neuropathy, leukodystrophy and encephalopathy, and autism.

Both tests use Claritas' dual-capture, dual-sequencing platform method.

"New York State is known for having a rigorous evaluation process," Claritas Chief Operating Officer Mary Ellen Cortizas said in a statement. "Today's approval is a key component of our quality and regulatory strategy."

The company's clinical laboratories are also CLIA and ISO 15189 certified, Claritas noted.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.